Literature DB >> 12493258

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

Chloe L Thio1, Eric C Seaberg, Richard Skolasky, John Phair, Barbara Visscher, Alvaro Muñoz, David L Thomas.   

Abstract

BACKGROUND: Although coinfection with HIV-1 and hepatitis B virus (HBV) is common, few long-term studies on liver-disease mortality in coinfected people have been undertaken. Our aim was to examine liver-related mortality among people at risk for HIV-1 and HBV infections.
METHODS: We used data from a multicentre, prospective cohort study to classify 5293 men who had sex with men, according to their HIV-1 antibody status, ascertained semiannually, and their hepatitis-B surface antigen status (HBsAg), which we ascertained at baseline. Mortality rates were estimated in terms of person-years and Poisson regression methods were used to test for significance of relative risks.
FINDINGS: 326 (6%) men were HBsAg positive, of whom 213 (65%) were HIV-1 positive. Of the 4967 HBsAg negative men, 2346 (47%) were infected with HIV-1. The liver-related mortality rate was 1.1/1000 person years, and was higher in men with HIV-1 and HBsAg (14.2/1000) than in those with only HIV-1 infection (1.7/1000, p<0.001) or only HBsAg (0.8/1000, p<0.001). In coinfected individuals, the liver-related mortality rate was highest with lower nadir CD4+ cell counts and was twice as high after 1996, when highly active antiretroviral therapy (HAART) was introduced.
INTERPRETATION: Individuals coinfected with HIV-1 and HBV, especially those with low CD4+ nadir counts, are at increased risk for liver-related mortality, underscoring the importance of prevention, identification, and comprehensive management of hepatitis B in people infected with HIV-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12493258     DOI: 10.1016/s0140-6736(02)11913-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  322 in total

1.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  Cancer in cohort of HIV-infected population: prevalence and clinical characteristics.

Authors:  Yong-xi Zhang; Xi-en Gui; Ya-hua Zhong; Yu-ping Rong; Ya-jun Yan
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-08       Impact factor: 4.553

3.  Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda.

Authors:  P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas
Journal:  Int J STD AIDS       Date:  2010-08       Impact factor: 1.359

4.  In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection.

Authors:  Liza M Cabuang; Tim Shaw; Margaret Littlejohn; Danni Colledge; Vitini Sozzi; Sally Soppe; Nadia Warner; Alex Thompson; Scott Preiss; Natasha Lam; Renae Walsh; Sharon R Lewin; Chloe L Thio; Gail Matthews; Stephen A Locarnini; Peter A Revill
Journal:  J Med Virol       Date:  2012-08       Impact factor: 2.327

5.  Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.

Authors:  Chloe L Thio; Laura Smeaton; Melissa Saulynas; Hyon Hwang; Shanmugam Saravanan; Shanmugam Saravan; Smita Kulkarni; James Hakim; Mulinda Nyirenda; Hussain S Iqbal; Umesh G Lalloo; Anand S Mehta; Kimberly Hollabaugh; Thomas B Campbell; Shahin Lockman; Judith S Currier
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

6.  Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons.

Authors:  Masako Mizusawa; David C Perlman; David Lucido; Nadim Salomon
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

7.  Achieving protection against HBV in HIV patients: Finding the best strategy.

Authors:  Jose Ignacio Vargas; Juan Pablo Arab; Daniela Jensen; Francisco Fuster
Journal:  Hum Vaccin Immunother       Date:  2016-08-15       Impact factor: 3.452

8.  Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.

Authors:  Narayan Dharel; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12

9.  Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.

Authors:  Amy C Sherman; Nirupama Trehanpati; Marybeth Daucher; Richard T Davey; Henry Masur; Shiv Kumar Sarin; Shyam Kottilil; Anita Kohli
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-11       Impact factor: 2.205

10.  Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.

Authors:  Ashwin Balagopal; Frances H Philp; Jacquie Astemborski; Timothy M Block; Anand Mehta; Ronald Long; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; David L Thomas; Stuart C Ray
Journal:  Gastroenterology       Date:  2008-03-29       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.